Clostridioides difficile is a type of bacteria that often affects people who have been taking antibiotics, GST Micro LLC ...

The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut ...

T he antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C.

[43] Fewer treatment failures occurred with vancomycin use, but the difference was not significant. Relapse rates were also similar between treatment groups. Cost differences should be considered ...

Purpose The pharmacology, clinical efficacy, safety, dosage and administration, and place in therapy of fidaxomicin for the treatment of Clostridium difficile infection (CDI) are reviewed.

The panelist discusses Rebyota, a treatment approved by the FDA for preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment for recurrent C difficile ...

Administration of antibiotics for C. difficile has unintended consequences and can create a vicious cycle of infection treatment, disruption of the healthy biome and a 25% increase in the risk of ...

Pharmaceuticals announced updates on Phase 3 Readiness for Ibezapolstat in C. difficile Infection based on recent FDA and EMA ...

The following is a summary of “Oral Capsule FMT Combined With Bezlotoxumab Is a Successful Rescue Protocol Following Failure ...

There are currently no C. difficile vaccines available, and the main treatment for the infection is a lengthy course of ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

Once C-diff is in the ascendancy it can be very hard to shift – the traditional treatment is antibiotics but a significant number of patients do not respond and are left with relentless and ...